Business Context and Reporting Period
Company: ImmuCell Corp.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 1997
Business Overview: ImmuCell is a biotechnology company focused on developing products to prevent and treat gastrointestinal infections and manufacturing nutritional milk proteins. Key products include First Defense and the Kamar Heatmount Detector. The company operates joint ventures (AgriCell and Clearwater Diagnostics) for lactoferrin production and water diagnostics.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 1997 | 9 Months Ended Sep 30, 1996 |
|---|---|---|
| Total Revenues | $3,128,525 | $3,281,430 |
| Net Loss | $(55,834) | $(253,549) |
| Net Loss Per Share | $(0.02) | $(0.11) |
| Cash and Equivalents (Ending) | $798,160 | $824,194 |
| Net Cash from Operating Activities | $2,817 | $(345,739) |
| Total Debt (Current + Long Term) | $1,029,646 | $1,028,487 |
| Working Capital | $1,154,920 | $1,405,099 |
| Stockholders' Equity | $1,827,223 | $1,877,214 |
Gross Margin: 55% for the nine months ended September 30, 1997 (up from 54% in the prior year period).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 5% ($153,000) compared to the prior year nine-month period. This was driven by a 60% drop in grant income ($186,000 decrease) and a 15% drop in collaborative R&D revenue ($10,000 decrease), partially offset by a 1% increase in product sales.
- Improved Profitability: Net loss improved significantly, narrowing from $253,549 in 1996 to $55,834 in 1997. This improvement was primarily due to a 28% reduction in R&D expenses ($316,000 decrease) and a 15% reduction in G&A expenses.
- Cash Flow Turnaround: Operating cash flow turned positive ($2,817) compared to a significant outflow of $(345,739) in the prior year, aided by reductions in inventory and accounts receivable.
- Debt Reduction: Total debt remained relatively stable, but the company made significant principal payments of $169,760 during the period.
Outlook, Risks, and Management Commentary
- Grant Funding: In September 1997, the company secured a $710,000 Phase II Small Business Innovation Research grant from the NIH to fund the development of TravelGAM (bovine anti-E. COLI immunoglobulins). No income from this grant was recognized in the current period.
- Joint Ventures: AgriCell has begun commercial production of bovine lactoferrin. Clearwater Diagnostics entered a distribution agreement for its Crypto-Scan water test in the UK. Operating results from these ventures are not yet material.
- Liquidity: Management believes current capital resources are sufficient to meet working capital requirements for the next 12 months.
- Future Outlook: The company expects to continue incurring operating losses as it invests in R&D to demonstrate efficacy in clinical trials and pursue corporate partners for funding.
- Risks: Reliance on grant funding (which decreased significantly in 1997) and the need for continued investment in R&D before profitability can be achieved.
Investor Verification Checklist
- Grant Sustainability: Verify the status and future disbursement schedule of the new $710,000 NIH grant, given the sharp decline in grant income in 1997.
- Joint Venture Viability: Assess the commercial progress and revenue potential of AgriCell and Clearwater Diagnostics, as these are key growth drivers.
- Debt Covenants: Review the terms of the $1.03 million in debt obligations, specifically the collateral requirements (receivables, inventory, fixed assets) and upcoming principal payments ($230,000 due in 1998).
- Product Concentration: Note that 94% of product sales are derived from two products (First Defense and Kamar Heatmount Detector); verify the stability of these sales channels.